Neumora Therapeutics (NMRA) officer sells 6,165 shares to cover RSU taxes

Rhea-AI Filing Summary

Neumora Therapeutics, Inc. officer Aurora Daljit Singh reported an open-market sale of 6,165 shares of common stock on February 17, 2026 at an average price of $3.555 per share. According to the filing, the shares were sold to satisfy tax withholding obligations tied to vesting restricted stock units. After this transaction, Singh directly owned 82,770 common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aurora Daljit Singh

(Last) (First) (Middle)

C/O NEUMORA THERAPEUTICS, INC.

260 ARSENAL WAY, SUITE 1

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Neumora Therapeutics, Inc. [ NMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		S(1)		6,165	D	$3.555	82,770	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

Remarks:

Title: Chief Operating and Development Officer

	/s/ Michael Milligan, as Attorney-in-Fact for Daljit Singh Aurora	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Neumora Therapeutics (NMRA) Form 4 report for Aurora Daljit Singh?

The Form 4 reports that officer Aurora Daljit Singh sold 6,165 shares of Neumora Therapeutics common stock at $3.555 per share. The sale was made to cover tax withholding obligations from vesting restricted stock units and was not a discretionary stock sale.

How many Neumora Therapeutics (NMRA) shares did Aurora Daljit Singh sell and at what price?

Aurora Daljit Singh sold 6,165 Neumora Therapeutics common shares at an average price of $3.555 per share. The transaction occurred on February 17, 2026 as an open-market sale linked to tax withholding on RSU vesting.

Why did Aurora Daljit Singh sell Neumora Therapeutics (NMRA) shares?

The shares were sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units. This means the disposition was related to meeting tax requirements rather than a voluntary reduction of the overall investment position in Neumora Therapeutics.

How many Neumora Therapeutics (NMRA) shares does Aurora Daljit Singh own after the Form 4 transaction?

After the reported sale, Aurora Daljit Singh directly owns 82,770 shares of Neumora Therapeutics common stock. This remaining stake is disclosed in the Form 4 and reflects holdings following the tax-related sale of 6,165 shares tied to RSU vesting.

Was the Neumora Therapeutics (NMRA) insider sale by Aurora Daljit Singh a routine tax-withholding transaction?

Yes. A footnote explains the 6,165-share sale was executed to satisfy tax withholding obligations from the vesting of restricted stock units. Such transactions are typically administrative and connected to equity compensation rather than a change in investment outlook.